<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04299282</url>
  </required_header>
  <id_info>
    <org_study_id>CPR-2205</org_study_id>
    <nct_id>NCT04299282</nct_id>
  </id_info>
  <brief_title>CIED Implantation in Low BMI Patients</brief_title>
  <official_title>A Prospective, Randomized, Single-Center Study Evaluating CanGaroo in Low BMI Patients Undergoing Pacemaker, ICD, or S-ICD Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziyo Biologics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aziyo Biologics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to demonstrate a better degree of healing at the incision site and a
      decrease in erosion with CanGaroo compared to control patients (no envelope, CIED alone).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-center, prospective, randomized, post-market study of patients undergoing
      implantation of a pacemaker, ICD, or S-ICD with or without CanGaroo using the same hydration
      solution. Twenty patients, randomized 1:1 for 10 in the treatment group and 10 in the control
      group, shall be enrolled. Follow-up visits include post-op and 3-months following the
      implantation procedure.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Postponed due to COVID-19 pandemic
  </why_stopped>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized 1:1 for 10 in the treatment group and 10 in the control group, shall be enrolled</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing at incision site</measure>
    <time_frame>3 months post CIED implantation</time_frame>
    <description>Improved incision site healing for the CanGaroo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QOL Survey</measure>
    <time_frame>3 months post CIED implantation</time_frame>
    <description>Patient assessment via Quality of Life Survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Tissue Layer</measure>
    <time_frame>3 months post CIED implantation</time_frame>
    <description>Ultrasound measurement of vascular tissue layer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Fold Test</measure>
    <time_frame>3 months post CIED implantation</time_frame>
    <description>Skin fold test measurement for tissue thickness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Diseases</condition>
  <condition>Cardiac Disease</condition>
  <arm_group>
    <arm_group_label>CanGaroo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The treatment group will receive a CanGaroo envelope with implantation of a CIED</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No CanGaroo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will not receive a CanGaroo envelope with implantation of a CIED</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CanGaroo</intervention_name>
    <description>CIED ECM envelope</description>
    <arm_group_label>CanGaroo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI of less than 23.

          -  Already scheduled for or a clinical decision made to have one of the following
             qualifying CIED implant procedures using a device cleared by the U.S. FDA:

               -  De novo pacemaker, ICD, or S-ICD;

               -  Upgrade or change out of existing CIED to a pacemaker, ICD, or S-ICD

          -  Clinically stable and able to tolerate procedure.

          -  Be able and willing to return for follow-up care through the 3-month visit.

          -  Must possess the ability to provide informed consent.

        Exclusion Criteria:

          -  Patients with a known sensitivity to porcine material.

          -  Participation in another clinical study.

          -  Active infection. Clinical diagnosis of an active infection at the time of CIED
             implant (CIED infection, pneumonia, UTI, endovascular, cellulitis, bacteremia, or
             other major systemic infection).

          -  Female patient who is pregnant, or planning to become pregnant during the length of
             the study.

          -  Prior history of a CIED infection, other prosthetic device infection, or endovascular
             infection, including endocarditis in the past 12 months.

          -  Life expectancy of less than 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Riebman, MD, MA</last_name>
    <role>Study Director</role>
    <affiliation>Aziyo Biologics, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.aziyo.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CIED, Pacemaker, ICD, S-ICD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

